Drugs / CAR-NK cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06967038 | Feb 2025 → Oct 2027 expected | Sjogren syndrome, lymphoma | Bangdong Gong | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-NK cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06967038 ↗ |
| Modality | Cell therapy | “CAR-NK cell therapy” NCT06967038 ↗ |
| Route | Other | “cell infusion” NCT06967038 ↗ |